NanoHive Medical Secures a Venture Debt Round to Continue to Propel Commercialization
Boston, MA., December 11, 2023 – OrthoSpineNews –
NanoHive Medical, LLC, a highly innovative spinal orthopedics company, is
pleased to announce the closing of a venture debt round to support continued
adoption of its proprietary Soft Titanium® interbody fusion devices. The debt
was provided by Kenston Capital Partners, LLC and its affiliates with Outcome
Capital, LLC acting as strategic and financial advisor to NanoHive Medical.
“This capital infusion allows the company to capture the attention of
leading surgeons and convert them to our best-in-class portfolio more
aggressively. As we continue to produce consecutive month-overmonth record
sales, Kenston Capital’s participation enables this trend to continue,” said
Patrick O’Donnell, CEO of NanoHive Medical.
NanoHive’s highly differentiated lattice structure provides enhanced
visualization and reduced density as compared to alternatives, while also
achieving sufficient durability and strength for biomechanical loads.
Specifically designed geometry using a rhombic dodecahedron cell structure
creates a base structure similar to cancellous bone, and provides ideal
biomechanical elastic modulus properties. Manufactured with 3D printed
titanium, the NanoHive interbody portfolio spans anterior and posterior lumbar,
as well as cervical applications.
“We were drawn both to the value of the underlying IP and the exciting
financial picture being painted from early, yet strong, commercial traction.
Kenston Capital was delighted to participate in this debt financing, and looks
forward to assisting other growth-stage life sciences and medical device
companies,” commented James Kenney, Managing Partner of Kenston Capital
Partners.
“At Outcome Capital, we pride ourselves in finding not only appropriate, but
innovative capital solutions for our clients to take their companies and
technologies to the next stage. It was a pleasure working with Kenston, and we
are excited to see NanoHive take their next commercial step,” noted Arnold
Freedman, Managing Partner of Outcome Capital.
About NanoHive Medical, LLC
NanoHive Medical is a pioneer and leading innovator in 3D printed spinal
interbody fusion implants and instrumentation. The company’s proprietary,
biomimetic Soft Titanium® technology clearly distinguishes their products in
the $1.9B spinal interbody fusion device market. The Hive™ portfolio of
interbody fusion devices offers surgeons and their patients a set of
exceptional characteristics, including optimal biomechanical elastic modulus
properties, precise diagnostic imaging capabilities, and ideal osteoblast cell
attraction and integration qualities. These features may consistently
contribute to strong fusion constructs and positive clinical experiences.
NanoHive Medical is located in Woburn, Massachusetts U.S.A
Contact: Patrick O’Donnell, CEO & President, Patrick.odonnell@nanohive.com
Website: www.nanohive.com
About Outcome Capital, LLC
Outcome Capital (outcomecapital.com) is a highly specialized life sciences
and healthcare advisory and investment banking firm, providing innovative
companies with a value-added, market-aligned approach to mergers &
acquisitions, partnering and corporate finance. The firm leverages its proven
‘strategy-led execution’ approach to value enhancement by assisting management
teams and their boards in navigating both financial and corporate markets and
implementing the best path for success. The firm’s strength stems from its
multi-disciplinary, industry experts who draw from their broad relationships
and a wide range of scientific, operational, strategic, and transactional
expertise across the value chain. Comprised of former CEOs, business
development executives, venture capitalists, PhD/MD-level scientists and
clinicians, and experienced commercialization experts, Outcome’s team is driven
to propel innovation from bench to bedside.
About Kenston Capital Partners, LLC
Kenston Capital Partners (kenstoncapital.com) provides senior secured
venture debt financing to highgrowth, early-stage technology & healthcare
companies. Through flexible and scalable transactions that leverage recent
equity financings, Kenston Capital Partners provides minimally dilutive capital
to enable our borrowers to execute on their growth and innovation trajectory.
Since 2005, the Partners of Kenston Capital have originated more than $100
million in venture loans to more than 60 companies.
###
